Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.76 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.64 |
| ▸ | TUBB | P07437 | 2/20 | 0.64 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.64 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.64 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.64 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.64 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.64 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.64 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.64 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.64 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.64 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.64 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.64 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.64 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.63 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15452189 | 0.90 | EPHX2 (0.70) | EPHX2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10307570 | 0.88 | EPHX2 (0.76) | EPHX2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL9958243 | 0.87 | TUBB4A (0.66) | EPHX2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6072546 | 0.87 | EPHX2 (1.00) | EPHX2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6689193 | 0.87 | EPHX2 (0.84) | EPHX2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1252875 | 0.85 | TUBB4A (0.86) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29750809 | 0.85 | TUBB4A (0.86) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6685824 | 0.85 | EPHX2 (0.85) | EPHX2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10307572 | 0.85 | ABCB1 (0.64) | EPHX2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3777085 | 0.84 | EPHX2 (0.80) | EPHX2TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2661266-B1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ANJI PHARMA (US) LLC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-9463170-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9463170-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2015-09-24 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | EPHX2 3913/4885TUBB4A 4494/4885TUBB 4478/4885 |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | EPHX2 3913/4885TUBB4A 4494/4885TUBB 4478/4885 |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | EPHX2 3913/4885TUBB4A 4494/4885TUBB 4478/4885 |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | EPHX2 3913/4885TUBB4A 4494/4885TUBB 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.